Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06251180 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 6 months later Dec 31, 2025 → Jun 30, 2027
See other at-risk trials from Guangzhou Lupeng Pharmaceutical Company LTD.

Record History

  1. Primary completion pushed from Dec 31, 2025 to Jun 30, 2027 Enrollment closed, study ongoing · Site details revisedv4 Show 2 more changesShow less
    • Enrollment closed, study ongoing
    • Site details revised
  2. Primary completion date: Dec 31, 2024 to Dec 31, 2025v3
  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Mar 1, 2024 to Apr 10, 2024 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Mar 1, 2024 to Apr 10, 2024
    • Site details revised
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label, multicentre Phase Ib study to evaluate the safety and preliminary efficacy of new generation Bruton Tyrosine Kinase inhibitor Rocbrutinib in combination to R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristin, Prednison) in adult patients with newly diagnosed, previously untreated B-cell Non-Hodgkin Lymphoma \[Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL) or Mantle Cell Lymphoma (MCL)\].
Trial Details
NCT Number NCT06251180
Lead Sponsor Guangzhou Lupeng Pharmaceutical Company LTD.
Conditions B-cell Non-Hodgkin Lymphoma
Enrollment 112 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov